Free Trial

Edwards Lifesciences (EW) Competitors

Edwards Lifesciences logo
$88.62 +2.15 (+2.49%)
As of 01:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

EW vs. HSIC, AMN, ISRG, ABT, and SYK

Should you buy Edwards Lifesciences stock or one of its competitors? MarketBeat compares Edwards Lifesciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edwards Lifesciences include Henry Schein (HSIC), AMN Healthcare Services (AMN), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), and Stryker (SYK). These companies are all part of the "medical" sector.

How does Edwards Lifesciences compare to Henry Schein?

Henry Schein (NASDAQ:HSIC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Henry Schein has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Henry Schein currently has a consensus target price of $86.83, indicating a potential upside of 13.35%. Edwards Lifesciences has a consensus target price of $95.65, indicating a potential upside of 7.93%. Given Henry Schein's higher probable upside, analysts plainly believe Henry Schein is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Henry Schein
1 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.36
Edwards Lifesciences
0 Sell rating(s)
9 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.79

Edwards Lifesciences has a net margin of 17.39% compared to Henry Schein's net margin of 2.95%. Henry Schein's return on equity of 15.44% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Henry Schein2.95% 15.44% 5.53%
Edwards Lifesciences 17.39%15.19%11.71%

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 0.9% of Henry Schein shares are held by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Edwards Lifesciences had 2 more articles in the media than Henry Schein. MarketBeat recorded 22 mentions for Edwards Lifesciences and 20 mentions for Henry Schein. Edwards Lifesciences' average media sentiment score of 0.98 beat Henry Schein's score of 0.68 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Henry Schein
8 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Edwards Lifesciences
14 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Edwards Lifesciences has lower revenue, but higher earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Henry Schein$13.18B0.66$398M$3.3123.14
Edwards Lifesciences$6.07B8.41$1.07B$1.8847.14

Summary

Edwards Lifesciences beats Henry Schein on 11 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to AMN Healthcare Services?

Edwards Lifesciences (NYSE:EW) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Edwards Lifesciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

In the previous week, Edwards Lifesciences had 9 more articles in the media than AMN Healthcare Services. MarketBeat recorded 22 mentions for Edwards Lifesciences and 13 mentions for AMN Healthcare Services. Edwards Lifesciences' average media sentiment score of 0.98 beat AMN Healthcare Services' score of 0.22 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edwards Lifesciences
14 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AMN Healthcare Services
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Edwards Lifesciences currently has a consensus target price of $95.65, indicating a potential upside of 7.93%. AMN Healthcare Services has a consensus target price of $25.29, indicating a potential downside of 13.74%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, research analysts clearly believe Edwards Lifesciences is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences
0 Sell rating(s)
9 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.79
AMN Healthcare Services
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Edwards Lifesciences has a net margin of 17.39% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Edwards Lifesciences17.39% 15.19% 11.71%
AMN Healthcare Services -0.95%18.01%5.19%

Edwards Lifesciences has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$6.07B8.41$1.07B$1.8847.14
AMN Healthcare Services$2.73B0.42-$95.70M-$0.87N/A

Summary

Edwards Lifesciences beats AMN Healthcare Services on 14 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$10.06B14.71$2.86B$8.2550.67
Edwards Lifesciences$6.07B8.41$1.07B$1.8847.14

83.6% of Intuitive Surgical shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 0.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Intuitive Surgical has a net margin of 28.15% compared to Edwards Lifesciences' net margin of 17.39%. Intuitive Surgical's return on equity of 15.98% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Intuitive Surgical28.15% 15.98% 14.07%
Edwards Lifesciences 17.39%15.19%11.71%

In the previous week, Intuitive Surgical had 19 more articles in the media than Edwards Lifesciences. MarketBeat recorded 41 mentions for Intuitive Surgical and 22 mentions for Edwards Lifesciences. Intuitive Surgical's average media sentiment score of 1.27 beat Edwards Lifesciences' score of 0.98 indicating that Intuitive Surgical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intuitive Surgical
33 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Edwards Lifesciences
14 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Intuitive Surgical has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Intuitive Surgical presently has a consensus target price of $576.71, indicating a potential upside of 37.96%. Edwards Lifesciences has a consensus target price of $95.65, indicating a potential upside of 7.93%. Given Intuitive Surgical's higher possible upside, research analysts clearly believe Intuitive Surgical is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intuitive Surgical
1 Sell rating(s)
7 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.67
Edwards Lifesciences
0 Sell rating(s)
9 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.79

Summary

Intuitive Surgical beats Edwards Lifesciences on 15 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Abbott Laboratories?

Edwards Lifesciences (NYSE:EW) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Edwards Lifesciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.3% of Edwards Lifesciences shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Edwards Lifesciences has a net margin of 17.39% compared to Abbott Laboratories' net margin of 13.90%. Abbott Laboratories' return on equity of 17.62% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Edwards Lifesciences17.39% 15.19% 11.71%
Abbott Laboratories 13.90%17.62%10.01%

Edwards Lifesciences currently has a consensus target price of $95.65, suggesting a potential upside of 7.93%. Abbott Laboratories has a consensus target price of $119.09, suggesting a potential upside of 35.65%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences
0 Sell rating(s)
9 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.79
Abbott Laboratories
0 Sell rating(s)
5 Hold rating(s)
19 Buy rating(s)
2 Strong Buy rating(s)
2.88

In the previous week, Abbott Laboratories had 13 more articles in the media than Edwards Lifesciences. MarketBeat recorded 35 mentions for Abbott Laboratories and 22 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 0.98 beat Abbott Laboratories' score of 0.94 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edwards Lifesciences
14 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Abbott Laboratories
24 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$6.07B8.41$1.07B$1.8847.14
Abbott Laboratories$44.33B3.45$6.52B$3.5724.59

Summary

Abbott Laboratories beats Edwards Lifesciences on 9 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Stryker?

Stryker (NYSE:SYK) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

In the previous week, Stryker had 9 more articles in the media than Edwards Lifesciences. MarketBeat recorded 31 mentions for Stryker and 22 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 0.98 beat Stryker's score of 0.96 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stryker
21 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Edwards Lifesciences
14 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

77.1% of Stryker shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 4.6% of Stryker shares are owned by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$25.12B4.62$3.25B$8.6435.06
Edwards Lifesciences$6.07B8.41$1.07B$1.8847.14

Stryker has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Edwards Lifesciences has a net margin of 17.39% compared to Stryker's net margin of 13.20%. Stryker's return on equity of 23.42% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Stryker13.20% 23.42% 11.04%
Edwards Lifesciences 17.39%15.19%11.71%

Stryker presently has a consensus target price of $395.48, indicating a potential upside of 30.54%. Edwards Lifesciences has a consensus target price of $95.65, indicating a potential upside of 7.93%. Given Stryker's higher possible upside, equities analysts plainly believe Stryker is more favorable than Edwards Lifesciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stryker
0 Sell rating(s)
6 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.73
Edwards Lifesciences
0 Sell rating(s)
9 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.79

Summary

Edwards Lifesciences beats Stryker on 9 of the 16 factors compared between the two stocks.

Get Edwards Lifesciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EW vs. The Competition

MetricEdwards LifesciencesMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$50.88B$7.11B$6.30B$23.23B
Dividend YieldN/A1.21%2.68%4.09%
P/E Ratio47.0145.3521.1430.87
Price / Sales8.4173.32548.7124.81
Price / Cash30.3225.1527.4419.43
Price / Book4.987.349.924.71
Net Income$1.07B$157.37M$3.56B$1.07B
7 Day Performance3.13%3.78%2.22%1.18%
1 Month PerformanceN/AN/AN/A0.84%
1 Year Performance13.49%3.90%36.80%27.78%

Edwards Lifesciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EW
Edwards Lifesciences
3.2403 of 5 stars
$88.62
+2.5%
$95.65
+7.9%
+10.7%$50.88B$6.07B47.0116,000
HSIC
Henry Schein
3.201 of 5 stars
$74.21
flat
$86.83
+17.0%
+9.6%$8.45B$13.18B22.4225,000
AMN
AMN Healthcare Services
1.637 of 5 stars
$27.65
0.0%
$25.29
-8.6%
+38.0%$1.07B$2.73BN/A2,664
ISRG
Intuitive Surgical
4.1862 of 5 stars
$438.10
flat
$579.33
+32.2%
-23.0%$155.16B$10.06B53.1017,021
ABT
Abbott Laboratories
4.9318 of 5 stars
$87.42
+0.0%
$119.43
+36.6%
-36.1%$152.25B$44.33B24.49115,000

Related Companies and Tools


This page (NYSE:EW) was last updated on 6/1/2026 by MarketBeat.com Staff.
From Our Partners